Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Teresa MurphyDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA.ORCID 0000-0002-9126-7506
Meagan KellyDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA.
Kai S ShimagakiDepartment of Computational and Systems Biology, and Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7580-4781
Thomas DeStefanisDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA.
Gabriel GaleotosDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA.
Myungjin LeeVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Qing WeiDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jan NovakDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Katharine J BarDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
John P BartonDepartment of Computational and Systems Biology, and Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-1467-421X
Rebecca M LynchDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA.ORCID 0000-0002-7188-8073
Funding
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1U01AI169767 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Katharine June Bar, Rebecca Marie Lynch · 2022 to 2026
$8.4M
Quantifying the fitness cost of HIV-1 resistance to broadly neutralizing antibodiesR01AI152770 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI LYNCH, REBECCA MARIE · 2020 to 2024
$3.6M
National Institute of Allergy and Infectious Diseases AI152770National Institute of Allergy and Infectious Diseases AI162236National Institute of Allergy and Infectious Diseases AI169767NIAID NIH HHS R01 AI152770NIAID NIH HHS U01 AI169767
6 · The paper itself
Abstract
Broadly neutralizing antibodies (bNAbs) provide a useful tool for HIV cure strategies because of their ability to target conserved regions on the envelope (Env) protein in the context of both virions and infected cells. One of the best-studied bNAbs is the CD4 binding site (CD4bs) antibody VRC01 and others in its class. A major obstacle to effective cure strategies with bNAbs is viral immune escape. A deeper understanding of escape pathways from VRC01-class antibodies in genetically diverse samples is needed. Using an
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dual role of glycosylation in resistance to CD4-binding site broadly neutralizing antibodies. · full record | OpenQuestion